Bristol Myers Squibb (NYSE:BMY) Releases Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Bristol Myers Squibb (NYSE:BMY) released its earnings results on Thursday. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25, FiscalAI reports. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the previous year, the firm earned $1.63 earnings per share. Bristol Myers Squibb’s revenue was up 6.9% compared to the same quarter last year.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

• Strong third-quarter execution led to raised 2026 guidance. Revenue increased 7% to approximately $13.1 billion, growth-portfolio sales rose 12%, and non-GAAP EPS guidance is now $6.35–$6.55.
• The growth portfolio is becoming increasingly diversified, with eight medicines each annualizing above $1 billion. Key contributors included BREYANZI, CAMZYOS, OPDUALAG, REVLIMID, and QVANTIG, whose sales grew 28% sequentially and are now annualizing above $1.3 billion.
• BMS reported encouraging pipeline progress, including positive registrational results for Zenbexus, admilparant, RYZ101, and arlo-cel. The company also expects multiple additional readouts through 2027, including milvexian, SOTYKTU in lupus, Cobenfy, and golcadomide.
• The company expects a significant $1.5 billion–$2 billion ELIQUIS revenue decline in 2027 as loss of exclusivity begins in Europe, while the broader legacy portfolio is expected to decline 3%–5% in 2026.
• Management highlighted execution risks and ongoing uncertainty around several programs, including mixed dose results for admilparant, the need to improve Cobenfy patient starts and repeat prescribing, and a temporary clinical pause for autoimmune CAR-T candidate zola-cel following a fatal septic pneumonia case.

Bristol Myers Squibb Trading Up 1.2%

Shares of Bristol Myers Squibb stock traded up $0.73 during trading hours on Thursday, hitting $61.30. The company’s stock had a trading volume of 9,709,498 shares, compared to its average volume of 12,014,263. Bristol Myers Squibb has a 1-year low of $43.19 and a 1-year high of $68.64. The business has a fifty day moving average of $62.98 and a 200 day moving average of $59.88. The company has a market capitalization of $125.22 billion, a PE ratio of 13.50, a P/E/G ratio of 0.31 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Third-quarter revenue rose 6.9% year over year to $13.07 billion, exceeding Wall Street’s roughly $12.72 billion estimate, while adjusted EPS of $1.35 also topped expectations. Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
• Positive Sentiment: The company’s newer-drug Growth Portfolio expanded 12% to $7.7 billion and generated nearly all of the quarterly revenue growth. Eliquis demand also supported results, strengthening confidence that newer products can offset pressure from older medicines. Bristol Myers Growth Drugs Hit $7.7 Billion
• Positive Sentiment: Bristol Myers raised its full-year revenue outlook to approximately $50 billion, reflecting stronger-than-expected demand for its newer medicines. Management also highlighted artificial intelligence as helping accelerate drug research, although the financial impact remains an area investors will monitor. Bristol Myers Lifts Sales Outlook as Newer Drugs Drive Growth
• Neutral Sentiment: The 17% year-over-year decline in adjusted EPS largely reflected deal-related accounting effects rather than deterioration in the underlying business, according to the earnings reaction. Bristol Myers Squibb Q3 Earnings and AI Research
• Negative Sentiment: Bristol Myers cut its 2026 EPS outlook because of higher in-process research and development charges. The reduction limits the benefit of the higher sales forecast and may keep investors focused on spending and earnings quality. Bristol Myers Cuts EPS Outlook but Raises Revenue Forecast
• Negative Sentiment: Opdivo sales fell short of expectations, creating concern about performance from one of Bristol Myers’ key established products and contributing to the initial pressure on the stock. Bristol Myers Slips on Opdivo Sales and Guidance Cut

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Truist Financial reissued a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Citigroup restated a “neutral” rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $65.50.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.